At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled / 60 target
Drug / intervention
ivonescimab +1 moredrug
Likely dose
ivonescimab 20mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.
In Brief
A Phase 2 clinical trial evaluating ivonescimab and irinotecan liposome for Extensive-stage Small-cell Lung Cancer. Completed, enrolled 60 participants across 1 site.
Signals
Enrolling ahead of pace
Detailed Summary
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed small cell lung cancer, who progressed on PD-(L)1 -based first-line therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-stage Small-cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
First PostedJun 2024
Enrollment StartOct 2024
Primary CompletionOct 2024
Study CompletionAug 2025
TodayJul 2026
First PostedJun 27, 2024
Enrollment StartOct 16, 2024
Primary CompletionOct 22, 2024
Study CompletionAug 27, 2025
TodayJul 2, 2026
Enrollment to primary: 6 daysPosted 2.0 years ago
Arms & Interventions
ivonescimab and irinotecan liposomeexperimental
Subjects receive ivonescimab plus irinotecan liposome until progression.
Drug: ivonescimabDrug: irinotecan liposome
Interventions
ivonescimabdrug
20mg/kg, IV, D1, Q3W
irinotecan liposomedrug
56.5mg/m\^2, IV, D1, Q2W